These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8936627)

  • 21. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
    Murakoshi M; Ikeda R; Fukui N; Nakayama T
    Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F
    BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case].
    Gotoh M
    Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
    Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
    Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS; Lee SH; Park KK; Yoo SJ; Chung BH
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
    Haillot O; Fraga A; Maciukiewicz P; Pushkar D; Tammela T; Höfner K; Chantada V; Gagnier P; Morrill B
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
    Montorsi F; Roehrborn C; Garcia-Penit J; Borre M; Roeleveld TA; Alimi JC; Gagnier P; Wilson TH
    BJU Int; 2011 May; 107(9):1426-31. PubMed ID: 21348912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation of tamsulosin treatment in men with lower urinary tract symptoms: a pilot study.
    Kobayashi M; Tokue A; Morita T
    Urol Int; 2006; 76(4):304-8. PubMed ID: 16679830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement.
    Nieminen T; Tammela TL; Kööbi T; Kähönen M
    J Urol; 2006 Dec; 176(6 Pt 1):2551-6. PubMed ID: 17085157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
    Kirby RS; Quinn S; Mallen S; Jensen D
    Int J Clin Pract; 2004 Jan; 58(1):6-10. PubMed ID: 14994963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia].
    Sakai S; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1996 Mar; 87(3):695-701. PubMed ID: 8709447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.
    Lowe FC
    Clin Ther; 1997; 19(4):730-42. PubMed ID: 9377617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.
    Barkin J; Guimarães M; Jacobi G; Pushkar D; Taylor S; van Vierssen Trip OB
    Eur Urol; 2003 Oct; 44(4):461-6. PubMed ID: 14499682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamsulosin: an overview.
    Chapple C; Andersson KE
    World J Urol; 2002 Apr; 19(6):397-404. PubMed ID: 12022708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model.
    Choi BR; Kim HK; Soni KK; Karna KK; Lee SW; So I; Park JK
    Drug Des Devel Ther; 2018; 12():1855-1863. PubMed ID: 29970959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.